

1                   **Governance is key to controlling SARS-CoV-2’s vaccine resistance**

2                   Kenichi W. Okamoto<sup>1\*</sup>, Luis F. Chaves <sup>2</sup>, Rodrick Wallace<sup>3</sup>, Robert G. Wallace<sup>4</sup>

3                   <sup>1</sup>Department of Biology, University of St. Thomas, St Paul, USA.

4                   <sup>2</sup>Instituto Conmmemorativo Gorgas de Estudios de la Salud, Ciudad de Panama, Panama

5                   <sup>3</sup>Department of Epidemiology, New York State Psychiatric Institute, New York City, USA

6                   <sup>4</sup>Agroecology and Rural Economics Research Corps, St Paul, USA

7                   \*Corresponding author. Email: [kenichi.okamoto@stthomas.edu](mailto:kenichi.okamoto@stthomas.edu)

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

1           **Abstract:** Little attention has been paid to governance’s impacts on the evolution of SARS-  
2           CoV-2, the virus that causes COVID-19. To evaluate such impacts on the evolution of  
3           vaccine resistance, we analyzed a stochastic compartmental model to quantify the risk a  
4           mutant strain capable of evading immunity emerges post-vaccine rollout. We calibrated the  
5           model with publicly available data for four territories in the Western Hemisphere  
6           qualitatively differing in pandemic interventions. The model shows an immune-evading  
7           strain to be readily selected over all infectivities in Texas. In Panama, only a high level of  
8           transmission permits immune evasion to evolve. No invasion appears likely in Costa Rica  
9           and Uruguay. Programs combining pharmaceutical and nonpharmaceutical interventions are  
10          best positioned to remove the epidemiological space SARS-CoV-2 needs to evolve vaccine  
11          resistance.

12  
13          **One Sentence Summary:** Modes of governance and production help set the evolutionary  
14          trajectories of vaccine resistance in SARS-CoV-2 before vaccine campaigns begin.

15

1       **Main Text:** Considerable attention has been paid to public health’s impacts on the spread of  
2       SARS-CoV-2, the virus that causes COVID-19. Mask mandates, shelter-in-place orders, and  
3       broader interventions, including healthcare access and eviction moratoriums, mitigate SARS-  
4       2 transmission, albeit to varying degrees (1). Despite the striking emergence of multiple  
5       variants of concern, far less attention has been directed to policy’s effects upon the evolution  
6       of the virus (2). Particularly troubling is how little modeling has been dedicated to policy’s  
7       influence on the evolution of viral resistance to COVID-19 vaccines, for many policymakers  
8       our putative exit out of the pandemic (3).

9  
10       Concerns about vaccine resistance may seem premature. Declines in vaccine effectiveness  
11       have indeed been documented across COVID variants, but the primary problem at hand still  
12       remains first getting millions around the world without vaccine access, atop those skeptical  
13       and hesitant, vaccinated (2). The issues of vaccine access and the evolution of resistance are  
14       intertwined, however. Delays, gaps, or reversals in vaccination and other interventions  
15       pursued in various combinations since the start of the pandemic have already set the  
16       trajectory for the evolution of immune evasion (3).

17

### 18       **Modeling governance’s impacts**

19       To evaluate the possible impacts of governance on the evolution in vaccine resistance, our  
20       group analyzed a stochastic model to quantify the risk that a mutant SARS-CoV-2 strain  
21       capable of evading immunity emerges 170 days following vaccine rollout. The novel strain  
22       evades both natural immunity and immunity acquired by vaccination, but in this model  
23       otherwise circulates similarly as the ancestral strain. We calibrated the model with publicly  
24       available data for four territories in the Western Hemisphere: Panama, Costa Rica, Texas,

1 and Uruguay. The four represent societies of relatively high Human Development Index  
2 (HDI), but also substantively different modes of governance and public health policy as they  
3 relate to responding to COVID-19.

4  
5 We assessed how readily such a novel strain spreads in an initially monomorphic, immune-  
6 susceptible viral population. We found the ability of the strain to spread depends on the  
7 impacts of territorial policies on the ancestral strain's epidemiology at the time the mutant  
8 emerges. While some of these effects are likely to be relatively constant, others are time-  
9 varying. The transmission coefficients of the ancestral strain on each day in each location are  
10 estimated using an Ensemble Kalman Filter (see Supplementary Methods and Figure S1) (4).

11  
12 We then calculated the daily evolutionary invasibility of a mutant virus  $\mu$  in each territory  
13 using a modified version of the basic reproductive number  $R_\mu$  for the novel strain, derived  
14 using the next-generation operator (Supplementary Mathematica Notebook File S3) (5). We  
15 describe details of the modeling in the Supplementary Methods. All code is publicly  
16 available at [github.com/kewok/immune\\_evasion](https://github.com/kewok/immune_evasion) and released under the GNU Public License  
17 (GPL 3).

18  
19 Figure 1 shows SARS-CoV-2 exposure (and immunity) steadily low in Panama and Costa  
20 Rica across the 170 days after vaccinations begin, low but slowly rising in Uruguay, and  
21 sharply rising in Texas. The results also show that as the vaccination campaign begins, public  
22 health policies in Texas readily select for an immune-evading strain over all infectivities  
23 (found above the invasibility threshold  $\log R_\mu = 0$ ). In Panama, only a high level of  
24 transmission ( $\uparrow \mu = 5$ ) permits immune evasion to evolve. No invasion appears likely in Costa

1 Rica. Even with rising exposure, resistance appears highly unlikely to successfully emerge in  
2 Uruguay.

3  
4 The four territories differ substantively in their public health responses to the pandemic. The  
5 University of Oxford's COVID-19 Government Response Tracker combines containment  
6 and closure policies, measures of population economic support, health system policies, and  
7 vaccine policies into a government response index (6). The index shows Panama, Costa Rica,  
8 and Uruguay engaged in the kinds of combinations of control efforts that U.S. COVID  
9 science leaders recently publicly denounced (7). To be sure, these campaigns are in flux.  
10 Panama eventually converged upon a full-spectrum response: masks, vaccines, and  
11 household support. Costa Rica's nonpharmaceutical program pivoted to depending largely on  
12 vaccines alone beginning in 2021. Uruguay's startling early successes were subsequently  
13 mitigated by demands to reopen the economy.

14  
15 The Oxford effort also compiles subnational control programs, including for U.S. states (8).  
16 Texas's responses were emblematic of an abandonment of COVID public health policies in  
17 the U.S. South, with minimal time under shelter-in-place, near-total reopening of businesses,  
18 and ending mask mandates despite new waves of COVID infection. Although Texas was  
19 among the first ten U.S. states to enact universal access to COVID vaccination (16 years and  
20 older), only 58% of Texans are fully vaccinated. That combination suggests SARS-CoV-2  
21 populations there experience early and incomplete vaccine exposure and the granular  
22 geography of high- and low-vaccinated microhabitats to which resistance best evolves in  
23 response (3).

24

1           **Rethinking governance and science**

2           Such arrays of pandemic-specific health policies appear to capture only a part of the variation  
3           in COVID population burden. One control theory model showed delays in responding alone  
4           degrade and destabilize governmental response capacity, whatever those interventions might  
5           be (9). The accumulating degradation promotes multiple infection waves of increasing  
6           severity, not unlike what we have seen across novel COVID variants. Dithering and  
7           denialism can amplify COVID's damage beyond any immediate wave. The control system  
8           itself tailspins into long-term, unstable dynamics of repeated crashes and overcorrections.  
9           Under this class of models, the disease endemicity many hoped with the Omicron wave is  
10          replaced with explosive spikes of increasing amplitude.

11  
12          The context of COVID-19 outcome can be expanded from public health responses to  
13          dominant modes of economic production. Across Mesoamerica and the Caribbean, clusters  
14          of countries for epidemiological variables such as the exponential growth rate, and COVID  
15          cases and deaths 100 days after detection of first case, were matched with clusters based on  
16          uneven development variables, including HDI, the WHO Universal Health Care index, and  
17          several trade indicators (10). In Mesoamerica and the Caribbean, trade openness was  
18          associated with increases in COVID cases and deaths. Increases in concentration of imports,  
19          a marker of uneven development, correlated significantly with increases in early epidemic  
20          growth and deaths, even while accounting for COVID mitigation and prevention policies, and  
21          human travel across countries.

22  
23          The implications of these lines of analysis extend beyond governance and public health  
24          practice and into research itself. A disease outbreak, for instance, represents more than a

1 convergence of susceptibles, the exposed and infected, and those who have recovered from  
2 infection. Public health interventions and traditional SEIR modeling from which such  
3 campaigns often take direction must reach beyond cataloguing the emergent properties of  
4 populations of interacting individuals (11). The broader social landscapes in which pathogens  
5 evolve drive disease outbreaks (10, 11). The causes for the evolution of diseases are found as  
6 much in the field of the social determinants of health as in the object of the pathogen or  
7 patient population.

8  
9 We can take matters a step further. Modes of governance and production represent more than  
10 the ways a society impacts population health. They often embody a society's dominant  
11 principles and the institutional cognition—how groups think—by which such values are  
12 turned into policies (11, 12). “Social determinants” of health in reality are *societal*  
13 *determinations* that are devised and acted upon by specific people (13). As our model  
14 suggests, statal and parastatal practices set many of the boundary conditions in time and  
15 space over which subsequent vaccine resistance in COVID-19 and any pandemics to follow  
16 likely emerge, long before any actual vaccination begins. More proactive and structural  
17 approaches to public health interventions must therefore be pursued to exit the rolling  
18 COVID trap and prevent novel pathogens from emerging out of the spillover queue.

19  
20 Here are two strategic objectives to start. First, implement a program of integrated  
21 pharmaceutical and nonpharmaceutical interventions that removes the epidemiological space  
22 SARS-CoV-2 needs to evolve vaccine resistance and other adaptive life history changes (14).  
23 If not the Zero COVID programs some countries have instituted, governments and

1 communities should implement timely, consistent, and collaborative programs across  
2 ministries or affinity groups that drive SARS-CoV-2 under its local rates of replacement.

3  
4 Second, with the bigger picture in mind, governance must pivot back to supporting modes of  
5 production such as agroecology, community-controlled forestry, and open medicine that, on  
6 the front end of disease emergence, retard new pathogens from spilling over into human  
7 populations, and, on the back end, place public health and economic development on  
8 mutually supportive trajectories (15). Whatever the principles around which they organize  
9 themselves, societies across the globe are otherwise unlikely to flourish in the face of the  
10 epidemiological and climatic consequences of acting as if they are little more than a stock  
11 market with a country attached.

12

### 13 **Acknowledgments**

14 The authors declare no financial or non-financial competing interests. The present work was  
15 conducted independently of any funding the authors have received.

16

### 17 **References and Notes**

- 18 1. B.Y. An, et al. Policy design for COVID-19: Worldwide evidence on the efficacies of  
19 early mask mandates and other policy interventions. *Public Administration Review* **81**, 1157  
20 (2021).
- 21 2. C.E. Wagner, C.M. Saad-Roy, B.T. Grenfell. Modelling vaccination strategies for COVID-  
22 19. *Nature Reviews Immunology* **22**, 139 (2022).
- 23 3. P.J. Gerrish, et al. How unequal vaccine distribution promotes the evolution of vaccine  
24 escape (2021); <https://www.medrxiv.org/content/10.1101/2021.03.27.21254453v3>.



- 1 4. R. Engbert, M.M. Rabe, R. Kliegl, S. Reich. Sequential data assimilation of the stochastic  
2 SEIR epidemic model for regional COVID-19 dynamics. *Bulletin of Mathematical Biology*  
3 **83**, 1 (2021).
- 4 5. O. Diekmann, J.A.P. Heesterbeek, J.A. Metz. On the definition and the computation of the  
5 basic reproduction ratio  $R_0$  in models for infectious diseases in heterogeneous populations.  
6 *Journal of Mathematical Biology* **28**, 365 (1990).
- 7 6. T. Hale T, et al.. Variation in government responses to COVID-19. (2021);  
8 [www.bsg.ox.ac.uk/covidtracker](http://www.bsg.ox.ac.uk/covidtracker).
- 9 7. E. Emanuel, M. Osterholm. China's Zero-Covid policy is a pandemic waiting to happen.  
10 (2022); <https://www.nytimes.com/2022/01/25/opinion/china-covid-19.html>
- 11 8. L. Hallas L, et al.. Variation in US States' COVID-19 policy responses (2021);  
12 [www.bsg.ox.ac.uk/covidtracker](http://www.bsg.ox.ac.uk/covidtracker).
- 13 9. R. Wallace. How policy failure and power relations drive COVID-19 pandemic waves: A  
14 control theory perspective. (2021); <https://hal.archives-ouvertes.fr/hal-03214718/document>
- 15 10. L.F. Chaves, et al. Trade, uneven development and people in motion: Used territories and  
16 the initial spread of COVID-19 in Mesoamerica and the Caribbean. *Socio-Economic*  
17 *Planning Sciences* (2021);  
18 <https://www.sciencedirect.com/science/article/pii/S0038012121001531>.
- 19 11. R. Wallace, et al., *Clear-Cutting Disease Control: Capital-Led Deforestation, Public*  
20 *Health Austerity, and Vector-Borne Infection* (Springer International Publishing, 2018).
- 21 12. S. Galea, S.M. Abdalla, J.L. Sturchio. Social determinants of health, data science, and  
22 decision-making: Forging a transdisciplinary synthesis. *PLOS Medicine* **17**, e1003174  
23 (2020).

- 1 13. J.M. Spiegel, J. Breilh, A. Yassi. Why language matters: insights and challenges in  
2 applying a social determination of health approach in a North-South collaborative research  
3 program. *Globalization and Health* **11**, 9 (2015).
- 4 14. K. Okamoto, et al., When might host heterogeneity drive the evolution of asymptomatic,  
5 pandemic coronaviruses? *Nonlinear Dynamics*, in press.
- 6 15. R. Levins, C. Lopez. Toward an ecosocial view of health. *International Journal of Health*  
7 *Services*, **29**, 261 (1999).

8 **Author contributions:** Each author's contribution(s) to the paper are listed here under the  
9 CRediT model.

10

- 11 Conceptualization: KWO, LFC, RW, RGW  
12 Methodology: KWO, LFC, RGW  
13 Investigation: KWO, LFC, RGW  
14 Visualization: KWO, LFC, RGW  
15 Funding acquisition: N/A  
16 Project administration: KWO, LFC, RGW  
17 Supervision: KWO, LFC, RGW  
18 Writing – original draft: KWO, LFC, RGW  
19 Writing – review & editing: KWO, LFC, RW, RGW

20

21 **Competing interests:** Authors declare that they have no competing interests.

22

23 **Data and materials availability:** All data are available in the main text or the supplementary  
24 materials.

25


## 26 **Supplementary Materials**

27 Supplementary materials, including data, figure code, coding libraries, supplementary methods,  
28 and GNU license are available at [https://github.com/kewok/immune\\_evasion](https://github.com/kewok/immune_evasion).

29 Supplementary Methods

30 Fig. S1

31



1

2

3

**Fig. 1.** Exposure via infection or vaccination (solid line) and evolutionary invasibility (dashed

4

lines) of an immune-evading mutant strain  $\mu$  across 170 days in four Western Hemisphere

5

territories with relatively high HDIs but qualitatively distinct public health strategies. (A)

6

Panama, (B) Costa Rica, (C) Texas and (D) Uruguay. In all panels, the solid black lines represent

7

the invasibility threshold ( $\log R_\mu = 0$ ). The blue lines represent invasibility of a mutant 5% as

8

infectious as the resident strain, the green lines the invasibility of a mutant half as infectious of

9

the resident strain, the purple lines the invasibility of mutants as infectious as the resident strain,

10

and the orange lines a mutant 500% as infectious as the resident strain.

11